46.83
price up icon1.14%   0.53
pre-market  Pre-market:  46.83  
loading
Biohaven Ltd stock is traded at $46.83, with a volume of 724.56K. It is up +1.14% in the last 24 hours and down -11.57% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$46.30
Open:
$45.66
24h Volume:
724.56K
Relative Volume:
0.75
Market Cap:
$4.69B
Revenue:
-
Net Income/Loss:
$-746.61M
P/E Ratio:
-6.2691
EPS:
-7.47
Net Cash Flow:
$-485.24M
1W Performance:
-4.51%
1M Performance:
-11.57%
6M Performance:
+19.10%
1Y Performance:
+53.04%
1-Day Range:
Value
$44.95
$47.20
1-Week Range:
Value
$43.18
$50.40
52-Week Range:
Value
$26.80
$62.21

Biohaven Ltd Stock (BHVN) Company Profile

Name
Name
Biohaven Ltd
Name
Phone
203-404-0410
Name
Address
215 CHURCH STREET, NEW HAVEN, CT
Name
Employee
239
Name
Twitter
@biohavenpharma
Name
Next Earnings Date
2022-11-07T13:30:00.000Z
Name
Latest SEC Filings
Name
BHVN's Discussions on Twitter

Compare BHVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BHVN 46.83 4.69B 0 -746.61M -485.24M -7.47
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-16-24 Initiated Jefferies Buy
Sep-04-24 Initiated Bernstein Outperform
Jul-24-24 Initiated Morgan Stanley Overweight
Feb-16-24 Initiated RBC Capital Mkts Outperform
Feb-06-24 Initiated UBS Buy
Dec-22-23 Initiated H.C. Wainwright Buy
Dec-08-23 Initiated Robert W. Baird Outperform
Jan-24-23 Initiated SVB Securities Outperform
Jan-04-23 Initiated JP Morgan Overweight
Dec-02-22 Initiated BTIG Research Buy
Oct-26-22 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-12-22 Initiated Piper Sandler Overweight
Aug-19-22 Downgrade Piper Sandler Overweight → Neutral
Aug-08-22 Downgrade Wedbush Outperform → Neutral
May-11-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-19-21 Resumed Morgan Stanley Equal-Weight
Aug-10-21 Downgrade UBS Buy → Neutral
Aug-03-21 Reiterated Canaccord Genuity Buy
Mar-11-21 Initiated UBS Buy
Dec-15-20 Initiated H.C. Wainwright Buy
Apr-17-20 Initiated Cowen Outperform
Feb-10-20 Downgrade Oppenheimer Outperform → Perform
Feb-06-20 Initiated Mizuho Buy
Nov-22-19 Initiated Wedbush Outperform
Jun-25-19 Reiterated Canaccord Genuity Buy
May-06-19 Initiated Goldman Buy
Apr-09-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19 Reiterated Needham Buy
Jul-03-18 Reiterated Needham Buy
Jul-02-18 Reiterated Needham Buy
Apr-05-18 Downgrade Barclays Overweight → Equal Weight
Feb-22-18 Reiterated Canaccord Genuity Buy
Dec-15-17 Initiated Canaccord Genuity Buy
Oct-03-17 Reiterated Needham Buy
View All

Biohaven Ltd Stock (BHVN) Latest News

pulisher
Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024
pulisher
Nov 20, 2024

Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart

Nov 20, 2024
pulisher
Nov 19, 2024

Biohaven Ltd. (NYSE:BHVN) Shares Sold by First Turn Management LLC - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Victory Capital Management Inc. Has $18.17 Million Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat

Nov 19, 2024
pulisher
Nov 16, 2024

Biohaven (NYSE:BHVN) Stock Price Down 8%Should You Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Acquisition of Biohaven Lt - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Biohaven's (BHVN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - The Malaysian Reserve

Nov 13, 2024
pulisher
Nov 13, 2024

Biohaven shares rise as TD Cowen lifts price target to $75 - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Royal Bank of Canada Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price - MarketBeat

Nov 13, 2024
pulisher
Nov 11, 2024

12,400 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by SpiderRock Advisors LLC - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Trend Tracker for (BHVN) - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 07, 2024

Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $61.92 - MarketBeat

Nov 07, 2024
pulisher
Nov 05, 2024

Biohaven Stock Soars on Drug Trial Results: Time to Jump In? - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Biohaven Ltd - GuruFocus.com

Nov 05, 2024
pulisher
Oct 31, 2024

(BHVN) Technical Data - Stock Traders Daily

Oct 31, 2024
pulisher
Oct 23, 2024

Biohaven's (BHVN) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Oct 23, 2024
pulisher
Oct 20, 2024

Cadent Capital Advisors LLC Invests $1.77 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat

Oct 20, 2024
pulisher
Oct 20, 2024

(BHVN) Trading Advice - Stock Traders Daily

Oct 20, 2024
pulisher
Oct 16, 2024

Scholar Rock stock could benefit from Biohaven's Ph3 results, Truist raises potential rally outlook - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

BofA sustains Buy rating on Biohaven shares, sees SMA trial upside By Investing.com - Investing.com South Africa

Oct 15, 2024
pulisher
Oct 15, 2024

BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com UK

Oct 15, 2024
pulisher
Oct 13, 2024

Analysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $61.92 - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha

Oct 11, 2024
pulisher
Oct 10, 2024

Biohaven Ltd. (NYSE:BHVN) Shares Acquired by AQR Capital Management LLC - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

(BHVN) Investment Analysis - Stock Traders Daily

Oct 09, 2024
pulisher
Oct 09, 2024

17,064 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Squarepoint Ops LLC - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Biohaven retains Outperform stock rating on clinical results By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Biohaven holds steady with $60 target on SMA trial optimism - Investing.com India

Oct 07, 2024
pulisher
Oct 07, 2024

Biohaven holds steady with $60 target on SMA trial optimism By Investing.com - Investing.com Australia

Oct 07, 2024
pulisher
Oct 07, 2024

Biohaven maintains Buy rating with $59 target amid SMA trial optimism By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Biohaven (NYSE:BHVN) Stock Price Up 4.9%Here's What Happened - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Vladimir Coric Buys Handful Of Shares In Biohaven - Simply Wall St

Oct 06, 2024
pulisher
Oct 04, 2024

Cantor Fitzgerald Reiterates "Overweight" Rating for Biohaven (NYSE:BHVN) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - MSN

Oct 04, 2024
pulisher
Oct 04, 2024

Analysts’ Recent Ratings Changes for Biohaven (BHVN) - Defense World

Oct 04, 2024
pulisher
Oct 03, 2024

Biohaven (NYSE:BHVN) Price Target Raised to $68.00 at JPMorgan Chase & Co. - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Biohaven (NYSE:BHVN) Shares Gap Up After Insider Buying Activity - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

John W. Childs Purchases 21,052 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Yahoo Finance

Oct 03, 2024
pulisher
Oct 03, 2024

Biohaven director Childs buys shares worth nearly $1 million By Investing.com - Investing.com South Africa

Oct 03, 2024
pulisher
Oct 03, 2024

Biohaven CEO Vlad Coric acquires $999,970 in company stock By Investing.com - Investing.com Australia

Oct 03, 2024
pulisher
Oct 03, 2024

Biohaven director Childs buys shares worth nearly $1 million - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

Biohaven CEO Vlad Coric acquires $999,970 in company stock - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Marshall Wace LLP Sells 677,724 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Lelezard.com

Oct 02, 2024
pulisher
Oct 02, 2024

Biohaven Ltd. (NYSE:BHVN) Shares Sold by Point72 Asset Management L.P. - MarketBeat

Oct 02, 2024
pulisher
Oct 01, 2024

Biohaven sets public offering price at $47.50 per share By Investing.com - Investing.com Australia

Oct 01, 2024
pulisher
Oct 01, 2024

Biohaven shares could see growth as MDD and bipolar studies advance, per TD Cowen - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Biohaven (NYSE:BHVN) Sees Strong Trading Volume - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

Biohaven sets public offering price at $47.50 per share - Investing.com

Oct 01, 2024

Biohaven Ltd Stock (BHVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):